Data Integrity Issues I n Pharmaceutical Quality Assurance : global perspective
Future Journal of Pharmaceuticals and Health Sciences · 10.07.2026 · 6 (3) · 32-53
DOI: 10.26452/fjphs.v6i3.795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 10.07.2026. Verfasst von {"name":"Gayatri Anil More","email":"gayatrimore716@gmail.com","affiliation": und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Data integrity is a fundamental principle in the pharmaceutical industry, ensuring that all data generated and maintained throughout drug development and manufacturing are accurate, complete, consistent, and reliable. Maintaining data integrity is essentia l for ensuring product quality, patient safety, and regulatory compliance. Failure to preserve accurate and trustworthy records can lead to serious consequences, including compromised patient safety, product recalls, regulatory actions, financial losses, a nd damage to a company's reputation. Consequently, pharmaceutical organizations worldwide place significant emphasis on implementing robust data governance systems and adhering to international regulatory requirements to safeguard data throughout its lifec ycle. Regulatory agencies such as the U.S. Food and Drug Administration, European Medicines Agency, and World Health Organization recognize data integrity as a critical component of Good Manufacturing Practice (GMP). As the foundation of pharmaceutical qua lity systems, data integrity supports regulatory approval, ensures the production of safe and effective medicines, and strengthens public confidence in healthcare products.
Zitieren
APA
More","email":"gayatrimore716@gmail.com","affiliation":, N. A., Tharunkumar","email":"gayatrimore716@gmail.com","affiliation, N., Muley","email":"gayatrimore716@gmail.com","affiliation":", N. P., Jaybhaye","email":"gayatrimore716@gmail.com","affiliation, N. S., Hatkar","email":"gayatrimore716@gmail.com","affiliation":, N. D., Phoke","email":"gayatrimore716@gmail.com","affiliation":", N. V., Lahane","email":"gayatrimore716@gmail.com","affiliation":, N. N., & Ingle","email":"gayatrimore716@gmail.com","affiliation":", N. A. (2026). Data Integrity Issues I n Pharmaceutical Quality Assurance : global perspective. Future Journal of Pharmaceuticals and Health Sciences, 6(3), 32-53. https://doi.org/10.26452/fjphs.v6i3.795
Vancouver
More","email":"gayatrimore716@gmail.com","affiliation": NA, Tharunkumar","email":"gayatrimore716@gmail.com","affiliation N, Muley","email":"gayatrimore716@gmail.com","affiliation":" NP, Jaybhaye","email":"gayatrimore716@gmail.com","affiliation NS, Hatkar","email":"gayatrimore716@gmail.com","affiliation": ND, Phoke","email":"gayatrimore716@gmail.com","affiliation":" NV, et al. Data Integrity Issues I n Pharmaceutical Quality Assurance : global perspective. Future Journal of Pharmaceuticals and Health Sciences. 2026;6(3):32-53. doi:10.26452/fjphs.v6i3.795
BibTeX
@article{Moreemailgayatrimoregmailcomaffiliation2026,
author = {More","email":"gayatrimore716@gmail.com","affiliation":, "name":"Gayatri Anil and Tharunkumar","email":"gayatrimore716@gmail.com","affiliation, "name":"G. and Muley","email":"gayatrimore716@gmail.com","affiliation":", "name":"Yogiraj P. and Jaybhaye","email":"gayatrimore716@gmail.com","affiliation, "name":"Sunil S. and Hatkar","email":"gayatrimore716@gmail.com","affiliation":, "name":"Avinash D. and Phoke","email":"gayatrimore716@gmail.com","affiliation":", "name":"Sandip V. and Lahane","email":"gayatrimore716@gmail.com","affiliation":, "name":"Shilpa N. and Ingle","email":"gayatrimore716@gmail.com","affiliation":", "name":"Sanket A.},
title = {Data Integrity Issues I n Pharmaceutical Quality Assurance : global perspective},
journal = {Future Journal of Pharmaceuticals and Health Sciences},
year = {2026},
volume = {6},
number = {3},
pages = {32--53},
doi = {10.26452/fjphs.v6i3.795}
}
EUVIMED